NICE recommends tocilizumab as a possible treatment for some children and young people with systemic juvenile idiopathic arthritis.

NICE does not recommend tocilizumab for children and young people whose disease is improving with methotrexate treatment, or who have not yet been treated with methotrexate.

Children and young people should be able to have tocilizumab if they have tried all of the following drugs but they have not worked:  NSAIDs (non-steroidal anti-inflammatory drugs), systemic corticosteroids and methotrexate.

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended tocilizumab because it is clinically effective and it is a cost effective use of NHS resources compared with other treatments currently used in clinical practice.  

  • National Institute for Health and Care Excellence (NICE) accreditation logo